311 related articles for article (PubMed ID: 34215453)
21. COVID-19 vaccination including 198 patients with history of severe anaphylactic reaction - own observations.
Wentrys Ł; Stopyra L
Przegl Epidemiol; 2021; 75(3):315-325. PubMed ID: 35170287
[TBL] [Abstract][Full Text] [Related]
22. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
24. Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.
Kaplan B; Farzan S; Coscia G; Rosenthal DW; McInerney A; Jongco AM; Ponda P; Bonagura VR
Ann Allergy Asthma Immunol; 2022 Feb; 128(2):161-168.e1. PubMed ID: 34699968
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.
Pool V; Braun MM; Kelso JM; Mootrey G; Chen RT; Yunginger JW; Jacobson RM; Gargiullo PM;
Pediatrics; 2002 Dec; 110(6):e71. PubMed ID: 12456938
[TBL] [Abstract][Full Text] [Related]
26. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
[No Abstract] [Full Text] [Related]
27. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
[TBL] [Abstract][Full Text] [Related]
28. Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
Maltezou HC; Hatziantoniou S; Theodoridou K; Vasileiou K; Anastassopoulou C; Tsakris A
Vaccine; 2023 Mar; 41(14):2382-2386. PubMed ID: 36872145
[TBL] [Abstract][Full Text] [Related]
29. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
[TBL] [Abstract][Full Text] [Related]
30. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights.
Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862
[TBL] [Abstract][Full Text] [Related]
31. Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
Myles IA; Vinciguerra JS; Premus RT
Vaccine; 2021 Jul; 39(32):4404-4406. PubMed ID: 34217573
[TBL] [Abstract][Full Text] [Related]
32. A Case Report of Prolonged Anaphylaxis after COVID-19 Vaccine.
Armstrong L; Maguire N
Clin Pract Cases Emerg Med; 2022 Feb; 6(1):21-24. PubMed ID: 35226841
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
34. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.
Montano D
Front Public Health; 2021; 9():756633. PubMed ID: 35186864
[TBL] [Abstract][Full Text] [Related]
35. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
36. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.
Shimabukuro T
Am J Transplant; 2021 Mar; 21(3):1332-1337. PubMed ID: 33641264
[No Abstract] [Full Text] [Related]
37. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.
Greenhawt M; Abrams EM; Shaker M; Chu DK; Khan D; Akin C; Alqurashi W; Arkwright P; Baldwin JL; Ben-Shoshan M; Bernstein J; Bingemann T; Blumchen K; Byrne A; Bognanni A; Campbell D; Campbell R; Chagla Z; Chan ES; Chan J; Comberiati P; Dribin TE; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Grayson MH; Horner CC; Hourihane J; Katelaris CH; Kim H; Kelso JM; Lang D; Ledford D; Levin M; Lieberman J; Loh R; Mack D; Mazer B; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Oppenheimer J; Perrett KP; Ramsey A; Rank M; Robertson K; Sheikh J; Spergel JM; Stukus D; Tang MLK; Tracy JM; Turner PJ; Whalen-Browne A; Wallace D; Wang J; Waserman S; Witry JK; Worm M; Vander Leek TK; Golden DBK
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3546-3567. PubMed ID: 34153517
[TBL] [Abstract][Full Text] [Related]
38. Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions.
Macy E; Pandya S; Sheikh J; Burnette A; Shi JM; Chung J; Gin N; Crawford W; Zhang J
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):827-836. PubMed ID: 34971845
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
40. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
